Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ipsen and BioMérieux Enter Into a Broad Partnership in Personalized Medicine

Published: Friday, March 11, 2011
Last Updated: Friday, March 11, 2011
Bookmark and Share
The two companies leverage combined expertise in therapeutics and in diagnostics to improve patient care.

Ipsen and bioMérieux announced that they have entered into a partnership to create a global collaboration in theranostics, with a focus on hormone-dependent cancers. The two companies have signed a framework agreement to leverage their expertise and resources to develop a personalized approach to medicine based on Ipsen’s broad portfolio of innovative compounds and bioMérieux’s diagnostic tests.

Both companies will jointly identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors (NETs) and pituitary tumors.

This novel partnership emphasizes Ipsen’s and bioMérieux’s expertise in the emerging field of personalized medicine, a concept based on the systematic use of individual patient molecular information to tailor specific preventive and therapeutic solutions. The early development of companion diagnostic tests and innovative compounds may accelerate early clinical proof of concept and support the registration of Ipsen clinical drug candidates.

“We are very pleased to build this partnership with Ipsen, which has developed over the years a significant scientific and medical expertise. Our goal is to reinforce personalized medicine and contribute through this partnership to the novel paradigm in medicine, which is increasingly “patient-driven” rather than “diseasedriven”,” said Prof. Christian Bréchot, Vice President of Institut Mérieux, in charge of medical and scientific affairs, and member of the bioMérieux board.

Dr. Claude Bertrand, Executive Vice President, Chief Scientific Officer of Ipsen stated: “We are delighted to accelerate the deployment of our personalized medicine programs in oncology through this broad partnership with bioMérieux”. Claude Bertrand added: “The shared vision and the cross-company synergies represent a unique opportunity to leverage early stage co-development of innovative products and biomarkers for patient care.”

Theranostics, the development of innovative therapeutic agents with diagnostic companion tests (taking into account an individual’s genetics or tumor molecular profile) may be key to improve treatment efficacy and safety through the identification of potential responding patients as well as in monitoring the response to a treatment. The creation of the Ipsen / bioMérieux partnership reflects the visionary convergence of medical and information technologies to serve individual patient’s needs.

Theranostics offers a cutting-edge solution to optimize healthcare by making sure the best medicine is available to the right patients. It may also accelerate the time to market of new compounds through an improved selection of patients enrolled in clinical trials, thereby helping to address the global challenge of R&D productivity.

bioMérieux is committed to making personalized medicine a reality by building partnerships to develop theranostics for infectious diseases, cancer and cardiovascular diseases. Some collaborations include Ipsen, Merck & Co. and GSK.

bioMérieux has made a sustained investment in high medical value biomarkers through in-house R&D programs, licensing and research collaborations. Theranostics development also leverages bioMérieux's unique hybrid business strategy: the high complexity CLIA lab of its subsidiary, bioTheranostics, allied with bioMérieux's global IVD business, supports aggressive development timelines while ensuring test availability wherever the drug is sold.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Microdroplet Reactors Mimic Living Systems
Researchers use microdroplets to study non-equilibrium reactions like those in living organisms.
Toxicity Testing With Cultured Liver Cells
Microreactor replaces animal testing.
Study Validates Analysis of Copy Number Variation in Miniaturized Reaction Volumes
Data shows that accurate and reproducible CNV results can be produced with IntelliQube using the Array Tape® consumable.
Spotlight on Acoustic Liquid Handling
Journal of Laboratory Automation special issue highlights how acoustic liquid handling enables breakthrough innovations.
Organs on Chips
Combining 3D cell culture with microfluidics, organs-on-chips could revolutionize toxicology testing for pharmaceuticals, foods, cosmetics, pesticides, and industrial chemicals.
Finding the Needle in a Microbial Haystack
After developing a novel investigational technology called PathoChip that can rapidly identify elusive microorganisms, a team of Penn Medicine researchers recently succeeded for the first time in identifying a pathogen in a patient sample, demonstrating the proof of principle that this technology can be used to identify pathogens in human disease.
Organ-on-a-Chip
In a step toward personalized drug testing, researchers coax human stem cells to form complex tissues.
Diagnosing Cancer from a Single Drop of Blood
What if a physician could effectively diagnose cancer from one drop of a patient’s blood?
Study Reveals Shared Behavior of Microbes And Electrons
Bacteria streaming through a lattice behave like electrons in a magnetic material.
Study Reveals Shared Behavior of Microbes and Electrons
Bacteria streaming through a lattice behave like electrons in a magnetic material.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!